Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR VIII
EGFR VIII - Associated Disease
- glioblastoma
- Source Database
- CIViC Evidence
- Description
- In a Phase II clinical trial, patients with Glioblastoma Multiforme (GBM), positive for EGFR VIII deletion mutation (N=65), were treated with the Rindopepimut cancer vaccine, and standard adjuvant temozolomide chemotherapy. Median progression free survival (PFS) was 9.2 months, and median overall survival (OS) was 21.8 months. A pivotal, randomized Phase III trial is currently underway.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/971
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/312
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Glioblastoma Multiforme
- Evidence Direction
- Supports
- Drug
- Rindopepimut
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25586468
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Rindopepimut | Sensitivity | true |